Printer Friendly

Research and Markets: Analyzing the Global CNS Market 2012.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/9zccjc/analyzing_the_glob) has announced the addition of the "Analyzing the Global CNS Market 2012" report to their offering.

The CNS market at a global scale is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms remain favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs.

The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, insomnia, major depressive disorder (MDD), Parkinson's disease (PD), migraine, schizophrenia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others. Antipsychotics were the largest CNS drug class. Patent expirations of key brands Seroquel and Zyprexa will form the main resistors to segmental growth through 2016. The CNS sector has struggled recently, as product classes that have dominated treatment areas have come under increasing pricing pressure from generics or have been plagued with safety concerns.

The top players in the CNS market at a global level at this time are Johnson & Johnson, Pfizer, GSK, Eli Lilly, etc. Several of the top-selling CNS drugs are likely to lose patent protection in the next three years enabling generics to flood the market and erode the sales figures of pharma companies. The CNS portfolios of J&J and GSK are particularly vulnerable as each will each face generic competition for three of their leading CNS drugs.

The report begins with an introduction to CNS disorders. We analyze the basic CNS disorders such as ADHD, Alzheimer's disease, epilepsy, insomnia, major depressive disorder (MDD), migraine, Parkinson's disease, and Schizophrenia.

With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of CNS disorders. Some of these novel emerging drug classes for CNS disorder treatment are analyzed in our report.

Key Topics Covered:

A. Executive Summary

B. Introduction to CNS Disorders

C. Global CNS Market

D. Factors Impacting the Market

E. Performance of Various Drug Classes

F. Upcoming/Recently Developed CNS Drugs

G. Global CNS Drugs Market Forecast

H. Competition in the Industry

I. Leading Industry Contributors

- AstraZeneca

- Eli Lilly

- GlaxoSmithKline

- Johnson & Johnson

- Pfizer

For more information visit http://www.researchandmarkets.com/research/9zccjc/analyzing_the_glob
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 12, 2012
Words:470
Previous Article:Research and Markets: Cyber Forensics. From Data to Digital Evidence.
Next Article:Research and Markets: A Scientific Introduction to the Engineering and Applications of Healthcare and Medical Textiles.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters